[go: up one dir, main page]

MX2023005930A - Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. - Google Patents

Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.

Info

Publication number
MX2023005930A
MX2023005930A MX2023005930A MX2023005930A MX2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A MX 2023005930 A MX2023005930 A MX 2023005930A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
lung cancer
antibody
combined pharmaceutical
kinase inhibitor
Prior art date
Application number
MX2023005930A
Other languages
English (en)
Inventor
Tao Liu
Xiquan Zhang
Xunqiang Wang
Ding Yu
Xiaole Zhan
Naiying Wu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023005930A publication Critical patent/MX2023005930A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica combinada de un anticuerpo anti-PD-L1 y un inhibidor de cinasa c-Met para tratar el cáncer de pulmón, y específicamente a una composición farmacéutica combinada de un anticuerpo anti-PD-L1 y N-(4-((7-((1-(ciclopentilamino)ciclopropil)metoxi)-6-metoxiquinol in-4-il)oxi)-3-fluorofenil)-N-(4-fluorofenil)ciclopropan-1,1-dime tilamida para tratar cáncer de pulmón y uso de la composición farmacéutica combinada en el tratamiento de cáncer de pulmón.
MX2023005930A 2020-11-26 2021-11-26 Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon. MX2023005930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011350770 2020-11-26
PCT/CN2021/133386 WO2022111618A1 (zh) 2020-11-26 2021-11-26 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物

Publications (1)

Publication Number Publication Date
MX2023005930A true MX2023005930A (es) 2023-05-29

Family

ID=81755321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005930A MX2023005930A (es) 2020-11-26 2021-11-26 Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.

Country Status (3)

Country Link
CN (1) CN116437957A (es)
MX (1) MX2023005930A (es)
WO (1) WO2022111618A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120322426A (zh) * 2022-12-08 2025-07-15 正大天晴药业集团股份有限公司 喹诺林化合物治疗卵巢癌的用途
CN120322232A (zh) * 2022-12-09 2025-07-15 正大天晴药业集团股份有限公司 喹诺林化合物治疗小细胞肺癌的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012200204B9 (en) * 2003-09-22 2015-02-26 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof
US10869924B2 (en) * 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
JP7030704B2 (ja) * 2016-02-05 2022-03-08 オリオニス バイオサイエンシズ ビーブイ 二重特異性シグナル伝達物質およびその使用
CN115057815A (zh) * 2018-03-02 2022-09-16 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
EP3762032A4 (en) * 2018-03-07 2021-12-22 Genmab A/S DRUG AND ANTIBODY ANTI-TISSUE FACTOR CONJUGATES, AND THEIR USE IN THE TREATMENT OF CANCER
CN111617243B (zh) * 2019-02-28 2023-12-19 正大天晴药业集团股份有限公司 喹啉衍生物与抗体的药物组合
CN111973739B (zh) * 2019-05-23 2024-02-13 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途

Also Published As

Publication number Publication date
CN116437957A (zh) 2023-07-14
WO2022111618A1 (zh) 2022-06-02

Similar Documents

Publication Publication Date Title
GEAP202315703A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2024009727A (es) Terapias de combinacion.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
EP4552631A3 (en) Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
SA522432955B1 (ar) Kras g12c مثبطات
MY208549A (en) Parp1 inhibitors
EA202190749A1 (ru) Способы комбинированной терапии
MY199409A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
NZ795548A (en) Allosteric egfr inhibitors and methods of use thereof
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2023010411A (es) Inhibidores de erbb/btk.
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
IL184791A (en) Gaffitinib-Resistant Cancer Treatment Compounds A method to treat gafitinib-resistant cancer with an EGFR gene t790m using irreversible EGFR inhibitors
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
NZ609283A (en) Compounds as c-met kinase inhibitors
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
CL2012002739A1 (es) Compuesto (r)-n-(3-(7-metil-1h-indazol-5-il)-1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida; composicion farmaceutica que lo comprende; uso del compuesto para el tratamiento de migraña, dolor neuropático, cancer de mama y glioma.
MX2023005930A (es) Composicion farmaceutica combinada de anticuerpo anti-ligando de muerte programada 1 e inhibidor de cinasa c-met para tratar cancer de pulmon.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres